june hancock mesothelioma research fund
june hancock mesothelioma research fund Company Information
Company Number
06249601
Website
www.junehancockfund.orgRegistered Address
riverside east, 2 millsands, sheffield, S3 8DT
Industry
Other human health activities
Telephone
01142744420
Next Accounts Due
March 2025
Group Structure
View All
Shareholders
-0%
june hancock mesothelioma research fund Estimated Valuation
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £25.4k based on a Turnover of £46.4k and 0.55x industry multiple (adjusted for size and gross margin).
june hancock mesothelioma research fund Estimated Valuation
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £0 based on an EBITDA of £-593.4k and a 4.8x industry multiple (adjusted for size and gross margin).
june hancock mesothelioma research fund Estimated Valuation
Pomanda estimates the enterprise value of JUNE HANCOCK MESOTHELIOMA RESEARCH FUND at £541k based on Net Assets of £227.7k and 2.38x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
June Hancock Mesothelioma Research Fund Overview
June Hancock Mesothelioma Research Fund is a live company located in sheffield, S3 8DT with a Companies House number of 06249601. It operates in the other human health activities sector, SIC Code 86900. Founded in May 2007, it's largest shareholder is unknown. June Hancock Mesothelioma Research Fund is a established, micro sized company, Pomanda has estimated its turnover at £46.4k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
June Hancock Mesothelioma Research Fund Health Check
Pomanda's financial health check has awarded June Hancock Mesothelioma Research Fund a 2 rating. We use a traffic light system to show it exceeds the industry average on 1 measures and has 5 areas for improvement. Company Health Check FAQs
1 Strong
2 Regular
5 Weak
Size
annual sales of £46.4k, make it smaller than the average company (£694.2k)
£46.4k - June Hancock Mesothelioma Research Fund
£694.2k - Industry AVG
Growth
3 year (CAGR) sales growth of -45%, show it is growing at a slower rate (5.6%)
-45% - June Hancock Mesothelioma Research Fund
5.6% - Industry AVG
Production
with a gross margin of 37.2%, this company has a comparable cost of product (37.2%)
37.2% - June Hancock Mesothelioma Research Fund
37.2% - Industry AVG
Profitability
an operating margin of -1278.2% make it less profitable than the average company (5.9%)
-1278.2% - June Hancock Mesothelioma Research Fund
5.9% - Industry AVG
Employees
with 1 employees, this is below the industry average (18)
- June Hancock Mesothelioma Research Fund
18 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- June Hancock Mesothelioma Research Fund
- - Industry AVG
Efficiency
resulting in sales per employee of £46.4k, this is equally as efficient (£47.2k)
- June Hancock Mesothelioma Research Fund
£47.2k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - June Hancock Mesothelioma Research Fund
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 164 weeks, this is more cash available to meet short term requirements (113 weeks)
164 weeks - June Hancock Mesothelioma Research Fund
113 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 69.4%, this is a higher level of debt than the average (25.5%)
69.4% - June Hancock Mesothelioma Research Fund
25.5% - Industry AVG
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND financials
June Hancock Mesothelioma Research Fund's latest turnover from June 2023 is £46.4 thousand and the company has net assets of £227.7 thousand. According to their latest financial statements, we estimate that June Hancock Mesothelioma Research Fund has 1 employee and maintains cash reserves of £684.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 46,420 | 93,701 | 52,645 | 285,753 | 176,605 | 82,315 | 68,644 | 89,161 | 117,147 | 108,709 | 192,636 | 108,767 | 201,761 | 157,388 |
| Other Income Or Grants | ||||||||||||||
| Cost Of Sales | ||||||||||||||
| Gross Profit | ||||||||||||||
| Admin Expenses | ||||||||||||||
| Operating Profit | ||||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | -557,708 | 36,475 | 50,816 | 286,294 | 97,223 | -2,094 | 75,597 | 73,414 | -323,535 | 63,011 | 130,888 | -86,688 | 195,507 | -34,671 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -557,708 | 36,475 | 50,816 | 286,294 | 97,223 | -2,094 | 75,597 | 73,414 | -323,535 | 63,011 | 130,888 | -86,688 | 195,507 | -34,671 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | -557,708 | 36,475 | 50,816 | 286,294 | 97,223 | -2,094 | 75,597 | 73,414 | -323,535 | 63,011 | 130,888 | -86,688 | 195,507 | -34,671 |
| Employee Costs | 0 | 0 | 0 | 0 | 0 | 156 | 321 | 221 | 173 | 0 | 0 | 120 | 158 | |
| Number Of Employees | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | |||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 882 | 0 | 0 | 443 | 0 | 537 | 1,440 | 36 | 36 | 971 | 1,135 | 129 | 1,130 | 2,524 |
| Cash | 684,332 | 741,425 | 680,669 | 631,773 | 418,740 | 298,761 | 275,693 | 324,148 | 395,694 | 538,313 | 460,681 | 474,675 | 436,630 | 343,886 |
| misc current assets | 59,212 | 60,264 | 70,131 | 67,708 | 64,189 | 61,209 | 61,001 | 58,044 | 54,830 | 51,477 | 51,841 | 0 | 0 | 0 |
| total current assets | 744,426 | 801,689 | 750,800 | 699,924 | 482,929 | 360,507 | 338,134 | 382,228 | 450,560 | 590,761 | 513,657 | 474,804 | 437,760 | 346,410 |
| total assets | 744,426 | 801,689 | 750,800 | 699,924 | 482,929 | 360,507 | 338,134 | 382,228 | 450,560 | 590,761 | 513,657 | 474,804 | 437,760 | 346,410 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 216,943 | 16,274 | 1,860 | 1,800 | 71,099 | 30,900 | 21,433 | 4,720 | 137,209 | 76,229 | 76,186 | 106,241 | 26,769 | 87,669 |
| total current liabilities | 216,943 | 16,274 | 1,860 | 1,800 | 71,099 | 30,900 | 21,433 | 4,720 | 137,209 | 76,229 | 76,186 | 106,241 | 26,769 | 87,669 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 299,776 | 0 | 0 | 0 | 0 | 15,000 | 0 | 136,404 | 136,404 | 14,050 | 0 | 61,980 | 17,720 | 60,977 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 299,776 | 0 | 0 | 0 | 0 | 15,000 | 0 | 136,404 | 136,404 | 14,050 | 0 | 61,980 | 17,720 | 60,977 |
| total liabilities | 516,719 | 16,274 | 1,860 | 1,800 | 71,099 | 45,900 | 21,433 | 141,124 | 273,613 | 90,279 | 76,186 | 168,221 | 44,489 | 148,646 |
| net assets | 227,707 | 785,415 | 748,940 | 698,124 | 411,830 | 314,607 | 316,701 | 241,104 | 176,947 | 500,482 | 437,471 | 306,583 | 393,271 | 197,764 |
| total shareholders funds | 227,707 | 785,415 | 748,940 | 698,124 | 411,830 | 314,607 | 316,701 | 241,104 | 176,947 | 500,482 | 437,471 | 306,583 | 393,271 | 197,764 |
| Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | ||||||||||||||
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 882 | 0 | -443 | 443 | -537 | -903 | 1,404 | 0 | -935 | -164 | 1,006 | -1,001 | -1,394 | 2,524 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 200,669 | 14,414 | 60 | -69,299 | 40,199 | 9,467 | 16,713 | -132,489 | 60,980 | 43 | -30,055 | 79,472 | -60,900 | 87,669 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | ||||||||||||||
| Investing Activities | ||||||||||||||
| capital expenditure | ||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | ||||||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 299,776 | 0 | 0 | 0 | -15,000 | 15,000 | -136,404 | 0 | 122,354 | 14,050 | -61,980 | 44,260 | -43,257 | 60,977 |
| share issue | ||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 299,776 | 0 | 0 | 0 | -15,000 | 15,000 | -136,404 | -9,257 | 122,354 | 14,050 | -61,980 | 44,260 | -43,257 | 293,412 |
| cash and cash equivalents | ||||||||||||||
| cash | -57,093 | 60,756 | 48,896 | 213,033 | 119,979 | 23,068 | -48,455 | -71,546 | -142,619 | 77,632 | -13,994 | 38,045 | 92,744 | 343,886 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -57,093 | 60,756 | 48,896 | 213,033 | 119,979 | 23,068 | -48,455 | -71,546 | -142,619 | 77,632 | -13,994 | 38,045 | 92,744 | 343,886 |
june hancock mesothelioma research fund Credit Report and Business Information
June Hancock Mesothelioma Research Fund Competitor Analysis
Perform a competitor analysis for june hancock mesothelioma research fund by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in S 3 area or any other competitors across 12 key performance metrics.
june hancock mesothelioma research fund Ownership
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND group structure
June Hancock Mesothelioma Research Fund has no subsidiary companies.
Ultimate parent company
JUNE HANCOCK MESOTHELIOMA RESEARCH FUND
06249601
june hancock mesothelioma research fund directors
June Hancock Mesothelioma Research Fund currently has 6 directors. The longest serving directors include Mr Adrian Budgen (May 2007) and Mr Adrian Budgen (May 2007).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Adrian Budgen | 61 years | May 2007 | - | Director | |
| Mr Adrian Budgen | 61 years | May 2007 | - | Director | |
| Ms Kate Hill | 71 years | Jun 2007 | - | Director | |
| Mrs Kimberley Stubbs | 58 years | Jun 2007 | - | Director | |
| Mr Russell Hancock | 66 years | Jun 2007 | - | Director | |
| Mr Daniel Small | 48 years | Feb 2008 | - | Director |
P&L
June 2023turnover
46.4k
-50%
operating profit
-593.4k
0%
gross margin
37.3%
+0.8%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2023net assets
227.7k
-0.71%
total assets
744.4k
-0.07%
cash
684.3k
-0.08%
net assets
Total assets minus all liabilities
june hancock mesothelioma research fund company details
company number
06249601
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
May 2007
age
17
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2023
previous names
N/A
accountant
TOM HENSHAW
auditor
-
address
riverside east, 2 millsands, sheffield, S3 8DT
Bank
C A F CASH
Legal Advisor
-
june hancock mesothelioma research fund Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to june hancock mesothelioma research fund.
june hancock mesothelioma research fund Companies House Filings - See Documents
| date | description | view/download |
|---|
